structural optimization of pharmaceuticals in order to expand the chemical structure scope and improve therapeutic activity against specific proteins. Several of the 1-aminocyclobutanecarboxylic acid derivatives produced in this way exhibited satisfactory antifungal activity in vitro compared with positive control boscalid. In vitro antifungal tests revealed that compound A21 had comparable, even higher
构象限制开关概念已被采用作为药物结构优化的主要工具,以扩大
化学结构范围并提高针对特定蛋白质的治疗活性。与阳性对照
啶酰菌胺相比,以此方式生产的几种1-
氨基
环丁烷甲酸衍
生物在体外表现出令人满意的抗真菌活性。体外抗真菌试验表明,化合物A21对立枯丝核菌( R.s.,
EC 50 = 0.03 mg/L)和灰葡萄孢( B.c.,
EC 50 = 0.04 mg/L)具有相当甚至更高的抗真菌活性。Fluxapyroxad(R.s.,
EC 50 = 0.02 mg/L;B.c.,
EC 50 = 0.20 mg/L)和
啶酰菌胺(R.s. ,
EC 50 = 0.29 mg/ L;B.c.,
EC )50 = 0.42 毫克/升)。此外,成功筛选到的化合物A20对猪
SDH具有良好的抑制活性,其IC 50值为3.73 μM,与fluxapyroxad(IC 50 = 3.76 μM)相比具有相当的药效。使用
SEM